Pregled bibliografske jedinice broj: 1237395
Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study
Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study // Journal of personalized medicine, 12 (2022), 7; 1037, 11 doi:10.3390/jpm12071037 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1237395 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Chronic Effects of Effective Oral Cannabidiol
Delivery on 24-h Ambulatory Blood Pressure and
Vascular Outcomes in Treated and Untreated
Hypertension (HYPER-H21-4): Study Protocol for a
Randomized, Placebo-Controlled, and Crossover
Study
Autori
Kumrić, Marko ; Božić, Joško ; Dujić, Goran ; Vrdoljak, Josip ; Dujić, Željko
Izvornik
Journal of personalized medicine (2075-4426) 12
(2022), 7;
1037, 11
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
hypertension ; cannabidiols ; heart rate variability ; arterial stiffness ; DehydraTECH2.0
Sažetak
Accumulating data from both human and animal studies suggest that cannabidiol (CBD) may be associated with improved cardiovascular function, markedly with regard to reduction in blood pressure and improved endothelial function. However, there is a lack of randomized studies to support these notions, especially in at-risk populations. The principal aim of this randomized, placebo-controlled, and crossover study is to examine the influence of chronic CBD administration on 24-h blood pressure in individuals with mild or moderate hypertension who are either untreated or receiving standard care therapy. The secondary aims of the study are to determine the safety and tolerability of 5 weeks of CBD administration, and to quantify the effect on arterial stiffness, CBD and vascular health biomarkers, inflammation, heart rate variability, and psychological well-being in both groups of patients. The present single-center study is designed as a triple blind (Participant, Investigator, Outcomes Assessor), placebo- controlled, crossover pilot study in which 70 hypertensive volunteers (aged 40-70 years) will receive DehydraTECH2.0 CBD formulation and placebo in a crossover manner. We believe that comprehensive analyses that will be performed in the present trial will decipher whether CBD is in fact a safe and valuable supplement for patients with treated and untreated hypertension.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
